Good Clinical Practice: Sponsor Responsibilities and Oversight

Comprehensive flashcards covering sponsor responsibilities, trial design, oversight, investigator selection, regulatory interactions, quality management, audits, and investigational product controls under Good Clinical Practice (ICH GCP E6).

What is the Good Clinical Practice (GCP) definition of a clinical trial sponsor?

An individual, company, institution, or organisation that takes responsibility for the initiation, management, and/or financing of a clinical trial.

Under regulatory requirements, can a clinical trial have more than one sponsor?

Yes, a clinical trial may have one or several sponsors where permitted under regulatory requirements.

What is the definition of a sponsor-investigator in the context of investigator-initiated trials (IIT)?

An individual who both initiates and conducts, alone or with others, a clinical trial, and under whose immediate direction the investigational product is administered to, dispensed to, or used by a trial participant.

Can an agency or a commercial corporation qualify as a sponsor-investigator?

No, the term sponsor-investigator does not include any person other than an individual (e.g., it does not include a corporation or an agency).

What scope of obligations applies to an individual acting as a sponsor-investigator?

The obligations of a sponsor-investigator include both those of a sponsor and those of an investigator.

Which clinical trial relationship model is represented in this organizational diagram?

A direct Sponsor-Investigator model where the sponsor engages the investigator, the investigator conducts the trial, and the sponsor directly monitors the clinical trial.

Which clinical trial management model is illustrated in this workflow diagram?

A delegated model where the sponsor engages a Contract Research Organisation (CRO), the CRO selects the investigator and monitors the clinical trial, and the investigator conducts the trial.

Which oversight and monitoring structure among the Sponsor, CRO, and Investigator is shown in this diagram?

A tripartite model where the CRO selects the investigator, the investigator conducts the clinical trial, and both the CRO and the sponsor monitor the clinical trial.

What pre-requisite safety and efficacy data must be confirmed by the sponsor during trial design planning?

The sponsor must ensure that sufficient safety and efficacy data (from nonclinical studies, clinical trials, and/or real-world sources) are available to support human exposure in the studied population.

Which specific administration parameters must pre-trial safety and efficacy data support before human exposure begins?

The route of administration, dosages, and treatment duration.

From which stakeholders should the sponsor consider inputs when designing a clinical trial?

A wide variety of interested parties, such as healthcare professionals and patients.

How should quality be integrated into the planning and design of a clinical trial?

By identifying factors that are critical to the quality of the trial and managing risks to those factors.

What operational design principles should the sponsor enforce to minimize trial complexity?

The design must be operationally feasible and avoid unnecessary complexity, unnecessary procedures, and unnecessary data collection.

What quality attributes are required for protocols, data acquisition tools, and operational trial documents?

They should be clear, concise, and consistent.

At what milestone must the sponsor define, establish, and allocate all trial-related activities?

Prior to initiating the clinical trial.

Which specialized professional roles must a sponsor utilize throughout all stages of the trial process?

Qualified individuals such as biostatisticians, clinical pharmacologists, and physicians.

In which key stages of a clinical trial must qualified experts be utilized by the sponsor?

Designing the protocol, designing Case Report Forms (CRFs), and analysing and preparing interim and final clinical trial reports.

What is the sponsor's responsibility regarding medical expertise for trial-related inquiries?

To designate appropriately qualified medical personnel who will be readily available to advise on specific trial-related medical questions or problems.

Is the sponsor permitted to hire external consultants for trial-related medical advice?

Yes, if necessary, outside consultant(s) may be appointed to advise on specific trial-related medical questions or problems.

Where must the financial arrangements of a clinical trial be officially documented?

In an agreement between the sponsor and the investigator and/or institution.

What general compliance statement must be included in the agreement between the sponsor and the investigator/institution?

An agreement to conduct the trial in compliance with the approved protocol, GCP, and applicable regulatory requirement(s).

What data handling obligation must be stipulated in the agreement between the sponsor and the investigator/institution?

An agreement to comply with procedures for data recording and reporting.

How long must investigators retain essential trial documents according to the sponsor-investigator agreement?

Until the sponsor explicitly informs the investigator/institution that these documents are no longer needed.

What access permissions must the investigator or institution guarantee in their agreement with the sponsor?

To permit monitoring and auditing by sponsors, inspections by regulatory authorities (domestic and foreign), and review by IRBs/IECs.

What specific facility and record access must be granted to oversight bodies under GCP agreements?

Direct access to source records and facilities, including those of service providers.

Can a sponsor transfer any or all of its trial-related duties and functions to a service provider (e.g., a CRO)?

Yes, a sponsor may transfer any or all of the sponsor's trial-related duties and functions to a service provider.

What happens to trial-related activities that are not specifically transferred to a service provider?

All trial-related activities that are not specifically transferred are retained by the sponsor.

Who holds ultimate responsibility for trial-related activities when tasks are delegated to a CRO?

The ultimate responsibility for the sponsor's trial-related activities resides with the sponsor.

In what format must any transfer of trial-related duties and functions to a service provider be established?

Any duty and function that is transferred should be specified in writing.

What internal system must a service provider implement when assuming delegated trial functions?

The service provider should implement appropriate quality management.

What type of incidents must a service provider report to the sponsor?

Incidents that might have an impact on the safety of trial participants or/and trial results.

What is the sponsor's responsibility regarding the selection and onboarding of a service provider?

The sponsor is responsible for assessing the suitability of and selecting the service provider, and providing them with the protocol and any other required operational documents.

What oversight obligation does a sponsor have over service providers performing transferred activities?

The sponsor must ensure oversight of important trial-related activities transferred to service providers and verify that they are conducted in accordance with relevant GCP/GMP requirements.

What requirement must be met when a clinical trial is conducted by more than one sponsor?

There should be a documented agreement that sets out their respective responsibilities.

What two fundamental qualifications must a sponsor verify when selecting an investigator or institution?

They must be qualified by training and experience and have adequate resources to properly conduct the trial.

What is required regarding the coordinating investigator(s) in multicentre clinical trials?

The roles and responsibilities of the coordinating investigator(s) should be documented.

What key trial documents must the sponsor supply to prospective investigators during selection?

The trial protocol and an up-to-date Investigator's Brochure (IB).

What provision must the sponsor make regarding investigator review of the study protocol?

The sponsor must provide the investigator with sufficient time to review the protocol and the information provided.

Why is an investigator's reputation in their field of expertise evaluated during site selection?

To assess their standing, professional competence, and track record in conducting trials within that specific therapeutic area.

What site infrastructure elements must be verified by the sponsor prior to investigator selection?

The availability of required trial equipment and adequately trained staff at the clinical trial site.

Why is the trial participant population evaluated at a potential investigator's site?

To ensure the availability of a suitable trial participant population for timely enrollment into the trial.

How do site accessibility and EC/IRB functionality influence investigator selection?

The sponsor must assess ease of accessibility to the site and the ability of the local EC/IRB to execute all its regulatory responsibilities effectively.

What timeline and schedule considerations are analyzed during investigator selection?

The anticipated time required to start and complete the trial.

Which budget components must be analyzed when selecting an investigator and site?

Investigator fees, coordinator fees, and specific procedure charges.

What digital capabilities should be assessed when evaluating an investigator's site readiness?

The site's capacity to manage digital tools such as eConsent and remote monitoring platforms.

What notification procedure must be followed when changing the Principal Investigator (PI) during an ongoing trial?

The current PI must inform the sponsor, the Ethics Committee (EC), and the Regulatory Authority (RA) and furnish them with the particulars of the new PI.

In Singapore, what regulatory authorization must be issued by the HSA before a new PI can conduct trials?

The new principal investigator must be issued a new CTA (Clinical Trial Authorisation), CTN (Clinical Trial Notification), or CTC (Clinical Trial Certificate) by the HSA.

What regulatory submission must the sponsor complete prior to initiating a clinical trial?

The sponsor must submit application(s) to the Regulatory Authority (RA) for review, acceptance, and/or permission to begin the trial.

What identifying information must appear on any formal notification or submission sent to a Regulatory Authority?

Any notification or submission should be dated and contain information identifying the protocol.

What confirmation must the sponsor obtain regarding the IRB before initiating a trial?

The sponsor must confirm that approval was issued by the IRB and obtain the IRB approval letter from the investigator.

In whose name is the official IRB approval letter issued?

The IRB approval letter is issued in the name of the investigator.

What specific details regarding the IRB/IEC must be documented and maintained in the sponsor's records?

The name and address of the IRB/IEC, a statement that it operates according to GCP and regulations, documented initial and subsequent approvals/favourable opinions, and trial terminations or suspensions.

What must the sponsor obtain if the EC conditions its approval upon trial modifications?

A copy of the modifications made (e.g., to protocol, informed consent form, or written subject information) and the date the recommendation was given by the EC.

What three core outcomes does sponsor oversight aim to safeguard regarding trial conduct and data?

To ensure reliable trial results, trial participants' safety, and appropriate decision making.

What compliance standards must sponsor oversight ensure during clinical trial processes?

Compliance with the trial protocol, applicable regulatory requirements, and ethical standards.

What criteria should a sponsor establish to classify a protocol deviation (PD) as 'important'?

Deviations that may significantly impact the completeness, accuracy, and/or reliability of trial data, or significantly affect a participant's rights, safety, or well-being.

How should the range and extent of sponsor oversight measures be calibrated?

They should be fit for purpose and tailored to the complexity and risks of the trial.

What is the operational goal of timely escalation and follow-up of issues in sponsor oversight?

To allow the implementation of corrective actions in a timely manner.

What is the primary function of an Independent Data Monitoring Committee (IDMC)?

To assess at intervals the progress of a clinical trial, including safety data and efficacy endpoints, and recommend whether to continue, modify, or stop a trial.

What is the primary function of an Endpoint Assessment Committee in a clinical trial?

To provide an independent, blinded, and standardized assessment of clinical endpoints to protect participant safety and enhance the reliability of trial results.

According to ICH GCP E6(R3) Section 3, what approach must sponsor responsibilities entail?

The implementation of risk-proportionate approaches to trial design, oversight, and quality management.

In which document must the sponsor describe the quality management approach implemented for the study?

In the clinical trial report.

Which three core trial components are covered under clinical Quality Management (QM)?

The design of trial protocols, tools and procedures for data collection and processing, and the collection of information essential to decision making.

What are the six sequential stages of the risk-based approach in Quality Management?

Risk Identification, Risk Evaluation, Risk Control, Risk Communication, Risk Review, and Risk Reporting.

What is the purpose of sponsor Quality Assurance (QA) and Quality Control (QC) systems with written SOPs?

To ensure that trials are conducted, and that data are generated, documented (recorded), and reported in compliance with the protocol, GCP, and applicable regulatory requirement(s).

How does a sponsor's QA audit differ conceptually and functionally from routine monitoring?

A sponsor's audit is independent of and separate from routine monitoring, designed to evaluate whether processes managing and conducting the trial are appropriate and compliant.

What two independence and qualification conditions must auditors satisfy?

They must be independent of the clinical trial/processes being audited and qualified by training and experience to conduct audits properly.

What formal deliverable should an auditor issue upon completing a clinical trial audit?

An audit certificate.

Is it permissible for a sponsor to ship investigational products to a site before obtaining IRB/IEC and RA approval?

No, shipping investigational products before receiving required approvals from both the IRB/IEC and Regulatory Authority is non-compliant and not appropriate.

What are the sponsor's financial, indemnification, and medical obligations regarding trial-related injuries?

The sponsor must provide insurance and indemnification (against non-malpractice claims) and implement policies addressing the costs of treatment for trial-related injuries.